Literature DB >> 27075496

Diastolic dysfunction in cirrhosis.

Søren Møller1, Signe Wiese2, Hanne Halgreen2, Jens D Hove3.   

Abstract

Development of esophageal varices, ascites, and hepatic nephropathy is among the major complications of cirrhosis. The presence of cirrhotic cardiomyopathy, which includes a left ventricular diastolic dysfunction (DD), seems to deteriorate the course of the disease and the prognosis. Increased stiffness of the cirrhotic heart may decrease the compliance and result in DD. The prevalence of DD in cirrhotic patients averages about 50 %. It can be evaluated by transmitral Doppler echocardiography, tissue Doppler echocardiography, and cardiac magnetic resonance imaging. There seems to be a relation between DD and the severity of liver dysfunction and the presence of ascites. After liver transplantation, DD worsens the prognosis and increases the risk of graft rejection, but DD improves after few months. Insertion of a transjugular intrahepatic portosystemic shunt increases left ventricular diastolic volumes, and DD is a predictor of poorer survival in these patients. Future studies should aim at disclosing pathophysiological mechanisms behind the developing of DD in cirrhosis in relation to patient characteristics, development of complications, treatment, and risk associated with interventional procedures.

Entities:  

Keywords:  Cardiac dysfunction; Cirrhotic cardiomyopathy; Hyperdynamic syndrome; Systolic dysfunction; Vasodilatation

Mesh:

Year:  2016        PMID: 27075496     DOI: 10.1007/s10741-016-9552-9

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  105 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?

Authors:  Kurt Lenz
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

3.  Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.

Authors:  M Huonker; Y O Schumacher; A Ochs; S Sorichter; J Keul; M Rössle
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

4.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

Review 5.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

6.  Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging.

Authors:  Konstantin Kazankov; Peter Holland-Fischer; Niels H Andersen; Peter Torp; Erik Sloth; Niels K Aagaard; Hendrik Vilstrup
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

7.  Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis.

Authors:  Søren Møller; Lise Hobolth; Christine Winkler; Flemming Bendtsen; Erik Christensen
Journal:  Gut       Date:  2011-04-19       Impact factor: 23.059

8.  Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study.

Authors:  Francisco Sampaio; Joana Pimenta; Nuno Bettencourt; Ricardo Fontes-Carvalho; Ana P Silva; João Valente; Paulo Bettencourt; José Fraga; Vasco Gama
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

9.  Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine.

Authors:  Luís Ruíz-del-Árbol; Linette Achécar; Regina Serradilla; Miguel Á Rodríguez-Gandía; Miguel Rivero; Elena Garrido; José J Natcher
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

Review 10.  Left ventricular diastolic function in hypertension: methodological considerations and clinical implications.

Authors:  Pasquale Palmiero; Annapaola Zito; Maria Maiello; Matteo Cameli; Pietro Amedeo Modesti; Maria Lorenza Muiesan; Salvatore Novo; Pier Sergio Saba; Pietro Scicchitano; Roberto Pedrinelli; Marco Matteo Ciccone
Journal:  J Clin Med Res       Date:  2014-12-29
View more
  13 in total

1.  Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?

Authors:  Karen V Danielsen; Signe Wiese; Jens Hove; Flemming Bendtsen; Søren Møller
Journal:  Dig Dis Sci       Date:  2018-03-08       Impact factor: 3.199

Review 2.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

3.  Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?

Authors:  Puria Nabilou; Karen Vagner Danielsen; Nina Kimer; Jens Dahlgaard Hove; Flemming Bendtsen; Søren Møller
Journal:  PLoS One       Date:  2022-06-28       Impact factor: 3.752

4.  TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.

Authors:  Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Mengcheng Shen; Vaibhav B Patel; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

Review 5.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

6.  Interplay of Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy.

Authors:  Csaba Matyas; Katalin Erdelyi; Eszter Trojnar; Suxian Zhao; Zoltan V Varga; Janos Paloczi; Partha Mukhopadhyay; Balazs T Nemeth; György Haskó; Resat Cinar; Robim M Rodrigues; Yeni Ait Ahmed; Bin Gao; Pal Pacher
Journal:  Hepatology       Date:  2020-01-24       Impact factor: 17.298

7.  Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits.

Authors:  Walid Nachar; Nolwenn Merlet; Foued Maafi; Yanfen Shi; Teodora Mihalache-Avram; Mélanie Mecteau; Marine Ferron; Eric Rhéaume; Jean-Claude Tardif
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

8.  Novel Findings From a Metabolomics Study of Left Ventricular Diastolic Function: The Bogalusa Heart Study.

Authors:  Alexander C Razavi; Lydia A Bazzano; Jiang He; Camilo Fernandez; Seamus P Whelton; Marie Krousel-Wood; Shengxu Li; Jovia L Nierenberg; Mengyao Shi; Changwei Li; Xuenan Mi; Jason Kinchen; Tanika N Kelly
Journal:  J Am Heart Assoc       Date:  2020-01-29       Impact factor: 5.501

9.  Exercise Training Attenuates Cirrhotic Cardiomyopathy.

Authors:  Sérgio Luiz Borges de Souza; Gustavo Augusto Ferreira Mota; Cristina Schmitt Gregolin; Milena do Nascimento; Renata Azevedo Melo Luvizotto; Silmeia Garcia Zanati Bazan; Mário Mateus Sugizaki; Luis Fernando Barbisan; Antonio Carlos Cicogna; André Ferreira do Nascimento
Journal:  J Cardiovasc Transl Res       Date:  2020-04-03       Impact factor: 4.132

10.  Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis.

Authors:  Soon Kyu Lee; Myeong Jun Song; Seok Hwan Kim; Hyo Jun Ahn
Journal:  Clin Mol Hepatol       Date:  2018-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.